Education and Training
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Darbepoetin
- drug: Placebo
Eligibility
Inclusion Criteria:
- Inborn and outborn preterm infants
- 23 0/7-28 6/7 weeks gestation
- ≤24 hours postnatal age
Exclusion Criteria:
- Hematocrit > 60%
- Infants with known congenital or chromosomal anomalies, including congenital heart
disease and known brain anomalies
- Hemorrhagic or hemolytic disease
- EEG- confirmed seizures
- Congenital thrombotic disease
- Systolic blood pressures >100 mm Hg while not on pressor support
- Receiving Epo or Darbe clinically, or planning to receive Epo or Darbe during
hospitalization
- Infants in whom no aggressive therapy is planned
- Family will NOT be available for follow-up at 22-26 months
Ages Eligible for Study
23 Weeks - 28 Weeks
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Krisa Van Meurs
6507235711
Not Recruiting